Atossa Therapeutics (ATOS)
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United S...
- Open
- 2.620
- High
- 2.620
- Low
- 2.500
- Prev. Close
- 2.640
- Volume
- 49.00K
- Turnover
- 124.87K
- Avg Price
- 2.548
- Bid/Ask Ratio
- --
- Amplitude
- 4.55%
- 52wk High
- 19.350
- Volume Ratio
- 0.75
- Turnover Ratio
- 0.57%
Atossa Therapeutics Analyst Rating
View moreForecast & Rating
Aug 14, 2026Price forecast
$18.67623.51%
Forecast & RatingBuy
2analysts
- Strong buy50.00%
- Buy50.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Earnings Watch · Aug 7 at 07:47 AM
Atossa Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
- TradingView · Aug 7 at 07:41 AM
ATOSSA THERAPEUTICS, INC. Q2 2026: Net loss $(8.49M), EPS $(0.95) — 10-Q Summary
- PUBT · Aug 7 at 07:32 AM
Atossa Therapeutics Q2 net loss widens to $18.1 million; reports no revenue
- StockTitan · Aug 6 at 11:45 PM
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | ATOS Stock News
- PUBT · Jul 28 at 07:30 AM
Atossa says novel endoxifen-related compounds show potent preclinical activity in ER-positive breast cancer models
- StockTitan · Jul 20 at 11:30 PM
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers | ATOS Stock News
